54
Participants
Start Date
June 25, 2015
Primary Completion Date
February 8, 2016
Study Completion Date
February 8, 2016
800 μg AZD7594 once daily
Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
250 µg AZD7594 once daily
Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
58 µg AZD7594 once daily
Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Placebo once daily
Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Salbutamol
Inhalation as needed
Research Site, Sofia
Research Site, Berlin
Research Site, Berlin
Research Site, Berlin
Research Site, Hamburg
Research Site, Hamburg
Research Site, Großhansdorf
Research Site, Lübeck
Research Site, Frankfurt
Research Site, Wiesbaden
Lead Sponsor
AstraZeneca
INDUSTRY